Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?

Although COVID-19 has captured most of the public health attention, antimicrobial resistance (AMR) has not disappeared. To prevent the escape of resistant microorganisms in animals or environmental reservoirs a "one health approach" is desirable. In this context of COVID-19, AMR has probab...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2022-06, Vol.13, p.921483
Main Authors: Pérez de la Lastra, José M, Anand, Uttpal, González-Acosta, Sergio, López, Manuel R, Dey, Abhijit, Bontempi, Elza, Morales delaNuez, Antonio
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - therapeutic use
Anti-Infective Agents - pharmacology
Anti-Infective Agents - therapeutic use
antibiotic discovery
antibiotic resistance
Antimicrobial Peptides
COVID-19 Drug Treatment
COVID-19 Vaccines
Drug Resistance, Bacterial
global health
Humans
Immunology
one health approach
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although COVID-19 has captured most of the public health attention, antimicrobial resistance (AMR) has not disappeared. To prevent the escape of resistant microorganisms in animals or environmental reservoirs a "one health approach" is desirable. In this context of COVID-19, AMR has probably been affected by the inappropriate or over-use of antibiotics. The increased use of antimicrobials and biocides for disinfection may have enhanced the prevalence of AMR. Antibiotics have been used empirically in patients with COVID-19 to avoid or prevent bacterial coinfection or superinfections. On the other hand, the measures to prevent the transmission of COVID-19 could have reduced the risk of the emergence of multidrug-resistant microorganisms. Since we do not currently have a sterilizing vaccine against SARS-CoV-2, the virus may still multiply in the organism and new mutations may occur. As a consequence, there is a risk of the appearance of new variants. Nature-derived anti-infective agents, such as antibodies and antimicrobial peptides (AMPs), are very promising in the fight against infectious diseases, because they are less likely to develop resistance, even though further investigation is still required.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.921483